These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2189835)

  • 41. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
    Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
    Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute epidemic aluminium osteomalacia secondary to water supply contamination.
    O'Brien AA; Moore DP; Keogh JA
    Ir J Med Sci; 1990 Mar; 159(3):71-3. PubMed ID: 2361822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 46. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity.
    Altmann P; Dhanesha U; Hamon C; Cunningham J; Blair J; Marsh F
    Lancet; 1989 Jul; 2(8653):7-12. PubMed ID: 2567838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis.
    Salusky IB; Coburn JW; Paunier L; Sherrard DJ; Fine RN
    J Pediatr; 1984 Nov; 105(5):717-20. PubMed ID: 6502300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide.
    Griswold WR; Reznik V; Mendoza SA; Trauner D; Alfrey AC
    Pediatrics; 1983 Jan; 71(1):56-8. PubMed ID: 6848980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical insufficiency fractures confused with Looser zones of osteomalacia.
    McKenna MJ; Kleerekoper M; Ellis BI; Rao DS; Parfitt AM; Frame B
    Bone; 1987; 8(2):71-8. PubMed ID: 3593610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Haemofiltration or haemodialysis in aluminium elimination?
    Sulkova S; Laurincova Z; Válek A
    Nephrol Dial Transplant; 1991; 6 Suppl 3():3-5. PubMed ID: 1775263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Aluminium in chronic renal replacement therapy patients undergoing haemodialysis in two renal units in Bogotá].
    Cárdenas O; Segura O; Puentes W; Sanabria M; Nava G; Torrenegra R
    Rev Salud Publica (Bogota); 2010 Aug; 12(4):669-81. PubMed ID: 21340131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Grand mal fitting in a patient on regular haemodialysis treatment and receiving desferrioxamine therapy.
    Davenport A; Ahmad R
    Scand J Urol Nephrol; 1988; 22(2):159-60. PubMed ID: 3144735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum and dialysate aluminium concentration of dialysed patients with chronic renal failure determined by atomic absorption spectrometry with a graphite furnace.
    Mazzeo-Farina A; Cerulli N
    Clin Chim Acta; 1985 Apr; 147(3):247-54. PubMed ID: 3995774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE; Prichard S
    Int J Artif Organs; 1986 May; 9(3):167-72. PubMed ID: 3733242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
    Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
    Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of aluminium on the effect of 1 alpha (OH)D3 on renal osteodystrophy.
    Shimada H; Nakamura M; Marumo F
    Nephron; 1983; 35(3):163-70. PubMed ID: 6633756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Water purification and the incidence of fractures in patients receiving home haemodialysis supervised by a single centre: evidence for "safe" upper limit of aluminium in water.
    Platts MM; Owen G; Smith S
    Br Med J (Clin Res Ed); 1984 Mar; 288(6422):969-72. PubMed ID: 6423163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.